CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer

The inhibitor of CDK4/6 has been clinically used for treating certain types of cancer which are characterized by G0/G1 acceleration induced by the CDK4/6-RB1 pathway. On the contrary, the cell cycle–related molecules are abnormal in over 50% of the patients with gastric cancer (GC), but the efficien...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhouying, Wang, Min, Li, Feng, Wang, Feng, Jia, Jianchao, Feng, Zongqi, Huo, Xue, Yang, Jie, Jin, Wen, Sa, Rina, Gao, Wenming, Yu, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427521/
https://www.ncbi.nlm.nih.gov/pubmed/34513922
http://dx.doi.org/10.3389/fmolb.2021.707295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427521/
https://www.ncbi.nlm.nih.gov/pubmed/34513922
http://dx.doi.org/10.3389/fmolb.2021.707295

Ejemplares similares